| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.2...
Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our...
Edward Jones analyst Soumit Roy initiates coverage on Evaxion (NASDAQ:EVAX) with a Buy rating and announces Price Target of ...
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powe...
Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and raises the price target from $6 to $11.